期刊文献+

转染甲状腺hNIS和hTPO基因的神经胶质瘤细胞摄碘功能的研究 被引量:5

Investigation of the radioiodine uptake function in the inferring hNIS and hTPO gene in human glioma cell line in vitro
原文传递
导出
摘要 目的在细胞水平研究转染人钠/碘转运体(hNIS)后的神经胶质瘤细胞的摄碘功能,为最终实现^(131)I治疗非甲状腺肿瘤提供理论依据。方法应用基因转染技术获得稳定表达hNIS的TJ- 905转以及hNIS和人甲状腺过氧化物酶(hTPO)瞬时共转染的TJ-905共,然后研究两种细胞的摄碘功能以及^(131)I的细胞毒作用。结果TJ-905转摄^(125)I活性增高(45.99±0.19)倍,其有效T_(1/2)约为5 min;TJ-905共的^(125)I有机化程度增高,有效T_(1/2)延长至10 min。同时TJ-905转的细胞增殖率降低,第7天降至(40.28±0.37)%,其细胞克隆存活率亦降至(31.83±0.52)%。结论转染hNIS基因的神经胶质瘤细胞具有较强的摄碘功能,并且^(131)I对其具有较强的抑制增殖作用。 Objective To provide an objective evidence for radioiodine therapy in nonthyroid tumor, we investigated the glioma cell's radioiodide uptake function. Methods Based on the cloning of human sodium/iodide(hNIS), stably expressing hNIS human glioma cell lines TJ-905-t and transient co-transfection of hNIS and hT-PO cell lines TJ-905-co were obtained, their radioactive 125I uptake function and ^131I inhibitory effect on cell proliferation were investigated. Results The uptake of ^125I was (45.99 ±0.19) times higher in TJ-905-t group than that in control group, its efficient half life was about 5 minutes. The amount of organified 125I present in TJ-905-co group was 4 times higher than that in TJ-905-t group. Furthermore, its efficient half life prolonged to 10 minutes. Moreover, the proliferative activity in TJ-905-t group declined gradually. It was (40.28± 0.37) % on the seventh day after seed, accordingly its colony formation number strikingly reduced to(31.83± 0.52)%. Conclusions After the transfection of hNIS gene, the uptake of ^125I was markedly higher in glioma cell lines, furthermore the inhibitory effect of^ 131I on cell proliferation was enhanced in TJ-905-t.
出处 《国际内分泌代谢杂志》 2007年第4期273-276,共4页 International Journal of Endocrinology and Metabolism
基金 天津市卫生局科技基金(2004ky47)
关键词 人甲状腺钠/碘转运体 人甲状腺过氧化物酶 基因转染 神经胶质瘤 ^131I治疗 Human sodium/iodide symporter Human thyroid peroxidase Gene transfection Glioma ^131I treatment
  • 相关文献

参考文献14

  • 1Rutka JT, Taylor M, Maintize T, et al. Molecular biology and neurosurgery in the third millennium. Neurosurgery,2000,46:1034-1051.
  • 2Boland A, Richard M, Opolon P, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res, 2000,60: 3484-3492.
  • 3Schipper ML, Weber A, Behe M, et al. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Cancer Res,2003,63 : 1333-1338.
  • 4Mandell RB, Mandell LZ, Link CJ. Radioisotope concentrator gene therapy using the sodlum/iodide symporter gene. Cancer Res, 1999,59 : 661- 668.
  • 5Boland A, Magnon C, Filetti S, et al. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid, 2002,12 : 19-26.
  • 6Spitzweg C, O'Connor MK, Bergen ER, et al.Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res,2000,60:6526-6530.
  • 7Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature, 1996,379: 458-460.
  • 8Smanik PA, Liu Q, Funninger TL, et al. Cloning of the human sodium/ iodide symporter. Biochem Biophys Res Commun, 1996,226:339-345.
  • 9Haberkom U, Henze M, Mtmann A, et al. Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med, 2001,42:317-325.
  • 10Smit JW,Schroder-van der Elst JP, Karprien M, et al. Expression of the sodium/iodide symporter (hNIS) in xerotransplanted human thyroid carcinoma. Exp Clin Endocrinol Diabetes, 2001,109 : 52-55.

同被引文献49

  • 1张一帆,李彪,赵龙,尤蓓,尹桂芝,贾世海,朱承谟.杆状病毒介导NIS基因放射治疗甲状腺癌的实验研究[J].中华核医学杂志,2004,24(5):264-267. 被引量:6
  • 2Cho JY, Shen DH, Yang W, et al. In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Ther, 2002,9:1139-1145.
  • 3Smanik PA, Liu Q, Furminger TL, et al. Cloning of the human sodium/iodide symporter. Biochem Biophys Res Commun, 1996,226: 339 -345.
  • 4Spitzweg C, Dietz AB, O'connor MK, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther, 2001,8: 1524-1531.
  • 5Mandell RB, Mandell LZ, Link CJ Jrl. Radioisotope concentrater gene therapy using the sodium/iodide symporter gene, Cancer Res, 1999,59:661-668.
  • 6Spitzweg C, O'connor MK, Bergert ER, et al. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res, 2000,60:6526-6530.
  • 7Smit JW, Schroder-van der Elst JP, Karperien M, et al. Expression of the human sodium/iodide symporter (hN1S) in xenotransplated human thyroid carcinoma. Exp Clin Endocrinol Diabetes, 2001, 109 :52-55.
  • 8Shimura H, Haraguchi K, Miyazaki A, et al. Iodide uptake and experimental ^131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene. Endocrinology, 1997,138:4493-4496.
  • 9Saito T, Endo T, Kawaguchia A, et al. Increased expression of the Na+/I- symporter in cultured human thyroid cells exposed to thyrotropin and in Graves' thyroid tissues. J Clin Endocrinol Metab, 1997,2:3331-3336.
  • 10Kogai T, Saito T, Endo T, et al, Regulation of thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology, 1997,138:2227-2232.

引证文献5

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部